BRPI0113155B8 - métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b - Google Patents

métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b Download PDF

Info

Publication number
BRPI0113155B8
BRPI0113155B8 BRPI0113155A BR0113155A BRPI0113155B8 BR PI0113155 B8 BRPI0113155 B8 BR PI0113155B8 BR PI0113155 A BRPI0113155 A BR PI0113155A BR 0113155 A BR0113155 A BR 0113155A BR PI0113155 B8 BRPI0113155 B8 BR PI0113155B8
Authority
BR
Brazil
Prior art keywords
hepatitis
vaccine
producing
methods
surface antigen
Prior art date
Application number
BRPI0113155A
Other languages
English (en)
Other versions
BR0113155A (pt
BRPI0113155C1 (pt
BRPI0113155B1 (pt
Inventor
De Heyder Koen
Serantoni Michelle
Van-Opstal Omer
Schu Peter
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR0113155A publication Critical patent/BR0113155A/pt
Publication of BRPI0113155B1 publication Critical patent/BRPI0113155B1/pt
Publication of BRPI0113155B8 publication Critical patent/BRPI0113155B8/pt
Publication of BRPI0113155C1 publication Critical patent/BRPI0113155C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b e para tratamento e/ou profilaxia de infeções pelo vírus da hepatite b, composição de vacina, uso de um antígeno de superfície para hepatite b, antígeno imunogênico de hepatite b e vacina". a presente invenção refere-se a um método para a produção de um antígeno para hepatite b adequado para uso em uma vacina, o método compreendendo a purificação do antígeno na presença de cisteína, para vacinas compreendendo tais antígenos.
BRPI0113155A 2000-08-10 2001-08-07 métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b BRPI0113155C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Publications (4)

Publication Number Publication Date
BR0113155A BR0113155A (pt) 2003-07-08
BRPI0113155B1 BRPI0113155B1 (pt) 2018-11-21
BRPI0113155B8 true BRPI0113155B8 (pt) 2019-08-13
BRPI0113155C1 BRPI0113155C1 (pt) 2021-05-25

Family

ID=26244821

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0113155A BRPI0113155C1 (pt) 2000-08-10 2001-08-07 métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b

Country Status (35)

Country Link
US (3) US20030235590A1 (pt)
EP (2) EP1666487B1 (pt)
JP (2) JP2004505992A (pt)
KR (1) KR100804922B1 (pt)
CN (1) CN1468256B (pt)
AP (1) AP2003002734A0 (pt)
AR (1) AR030325A1 (pt)
AT (2) ATE412665T1 (pt)
AU (2) AU8207301A (pt)
BG (1) BG66038B1 (pt)
BR (1) BRPI0113155C1 (pt)
CA (2) CA2427475C (pt)
CY (2) CY1106310T1 (pt)
CZ (1) CZ303217B6 (pt)
DE (2) DE60116107T2 (pt)
DK (2) DK1666487T3 (pt)
DZ (1) DZ3470A1 (pt)
EA (1) EA006433B1 (pt)
EG (1) EG25829A (pt)
ES (2) ES2254464T3 (pt)
HU (1) HU228932B1 (pt)
IL (2) IL154301A0 (pt)
MX (1) MXPA03001235A (pt)
MY (1) MY128999A (pt)
NO (1) NO20030635L (pt)
NZ (1) NZ524012A (pt)
OA (1) OA12361A (pt)
PE (1) PE20020287A1 (pt)
PL (1) PL204736B1 (pt)
PT (1) PT1666487E (pt)
SI (2) SI1307473T1 (pt)
SK (2) SK288079B6 (pt)
UA (1) UA79735C2 (pt)
UY (1) UY26882A1 (pt)
WO (1) WO2002012287A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
ATE526036T1 (de) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
WO2009057699A1 (ja) * 2007-10-30 2009-05-07 Kyocera Corporation 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
AU2009248810B2 (en) * 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2010252012A1 (en) * 2009-05-27 2011-12-22 Glaxosmithkline Biologicals S.A. CASB7439 constructs
DK2705365T3 (en) * 2011-01-14 2016-10-24 Hal Allergy Holding B V Immunoassay for the direct determination of the antigen content in the products containing the adjuvant-linked antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GEP20227386B (en) 2017-07-18 2022-06-10 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
TW202102256A (zh) 2019-03-05 2021-01-16 比利時商葛蘭素史密斯克藍生物品公司 B型肝炎免疫法及組合物
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0135435A3 (en) 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
FI932248L (fi) 1991-09-18 1993-07-02 Amgen Inc Hepatit b-vaccinkomposition innehaollande ett gallsyrasalt
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1999045957A2 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
CA2355680A1 (en) * 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
CY1106310T1 (el) 2011-10-12
BG107545A (bg) 2004-01-30
US20060159705A1 (en) 2006-07-20
OA12361A (en) 2004-04-13
BR0113155A (pt) 2003-07-08
ES2254464T3 (es) 2006-06-16
CY1108789T1 (el) 2014-04-09
AU8207301A (en) 2002-02-18
JP5559847B2 (ja) 2014-07-23
CN1468256A (zh) 2004-01-14
DE60116107T2 (de) 2006-08-03
KR100804922B1 (ko) 2008-02-20
SI1666487T1 (sl) 2009-02-28
PL204736B1 (pl) 2010-02-26
AU2001282073B2 (en) 2005-01-20
US20030235590A1 (en) 2003-12-25
CA2427475C (en) 2011-07-05
US8624004B2 (en) 2014-01-07
CZ303217B6 (cs) 2012-05-30
ES2314555T3 (es) 2009-03-16
SK1692003A3 (en) 2003-08-05
EA200300129A1 (ru) 2003-10-30
UA79735C2 (uk) 2007-07-25
PT1666487E (pt) 2008-12-26
ATE313558T1 (de) 2006-01-15
AR030325A1 (es) 2003-08-20
MY128999A (en) 2007-03-30
HUP0302951A3 (en) 2004-10-28
BG66038B1 (bg) 2010-11-30
IL154301A (en) 2009-11-18
PE20020287A1 (es) 2002-06-20
ATE412665T1 (de) 2008-11-15
CN1468256B (zh) 2010-10-27
EP1666487A1 (en) 2006-06-07
EP1307473B1 (en) 2005-12-21
BRPI0113155C1 (pt) 2021-05-25
MXPA03001235A (es) 2004-07-16
NO20030635L (no) 2003-04-01
UY26882A1 (es) 2002-03-22
EP1307473A1 (en) 2003-05-07
DK1666487T3 (da) 2009-01-12
IL154301A0 (en) 2003-09-17
KR20030029127A (ko) 2003-04-11
EG25829A (en) 2012-09-02
SI1307473T1 (sl) 2006-04-30
EP1666487B1 (en) 2008-10-29
WO2002012287A1 (en) 2002-02-14
CA2427475A1 (en) 2002-02-11
NO20030635D0 (no) 2003-02-07
US20090123496A1 (en) 2009-05-14
HUP0302951A2 (hu) 2003-12-29
JP2012255015A (ja) 2012-12-27
JP2004505992A (ja) 2004-02-26
DE60116107D1 (de) 2006-01-26
DZ3470A1 (fr) 2002-02-14
DE60136400D1 (de) 2008-12-11
CZ2003385A3 (cs) 2003-06-18
NZ524012A (en) 2004-02-27
HK1056884A1 (en) 2004-03-05
DK1307473T3 (da) 2006-05-01
CA2740282A1 (en) 2002-02-11
SK288079B6 (sk) 2013-06-03
BRPI0113155B1 (pt) 2018-11-21
AP2003002734A0 (en) 2003-03-31
PL362322A1 (en) 2004-10-18
EA006433B1 (ru) 2005-12-29
SK288069B6 (sk) 2013-05-03
HU228932B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
FR2814958B1 (fr) Composition vaccinale
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
JP2004505992A5 (pt)
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
EP1305042A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
ECSP034474A (es) Nuevo tratamiento
DK1237571T3 (da) Toscana-virus-nukleinprotein
AR035166A1 (es) Composiciones mejoradoras inmunomoduladoras y neutralizantes de anticuerpos. vacuna y metodo de tratamiento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2498 DE 21/11/2018, QUANTO AO ITEM (54) TITULO E AO QUADRO REIVINDICATORIO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/08/2021